Highlights of This Issue 6059

SPECIAL FEATURES

CCR Translations

6061 Harnessing Immune Responses in the Tumor Microenvironment: All Signals Needed
Dung T. Le and Elizabeth M. Jaffee
See related article, p. 6286

6064 Test-Firing Ammunition for Spliceosome Inhibition in Cancer
Scott M. Dehm
See related article, p. 6296

CCR Perspectives in Drug Approval

6067 Enzalutamide for Treatment of Patients with Metastatic Castration-Resistant Prostate Cancer Who Have Previously Received Docetaxel: U.S. Food and Drug Administration Drug Approval Summary
Yangmin M. Ning, William Pierce, Stella Karuri, Sheng-Hui Tang, Todd Palmby, Jeanne Faurie Zirkelbach, Dhananjay Marathe, Nitin Mehrotra, Qi Liu, Debasis Ghosh, Christy L. Cottrell, John Leighton, Rajeshwari Srihara, Amna Ibrahim, Robert Justice, and Richard Pazdur

Molecular Pathways

6074 Molecular Pathways: Adipose Inflammation as a Mediator of Obesity-Associated Cancer
Louise R. Howe, Kotha Subbaramaiah, Clifford A. Hudis, and Andrew J. Dannenberg

6084 Molecular Pathways: Induction of Polyploidy as a Novel Differentiation Therapy for Leukemia
Diane S. Krause and John D. Crispino

Review

6089 Lessons Learned from Radiation Oncology Clinical Trials
Fei-Fei Liu, for the workshop participants, Paul Okunieff, Eric J. Bernhard, Helen B. Stone, Stephen Yoo, C. Norman Coleman, Bhadrasarain Vikram, Martin Brown, John Buatti, and Chandan Guha

HUMAN CANCER BIOLOGY

6101 Semaphorin 4F as a Critical Regulator of Neuroepithelial Interactions and a Biomarker of Aggressive Prostate Cancer
Yi Ding, Dandan He, Diego Florentin, Anna Frolov, Sue Hilsenbeck, Michael Ittmann, Dov Kadmom, Brian Miles, David Rowley, and Gustavo Ayala

6112 Prostate Cancer Progression Correlates with Increased Humoral Immune Response to a Human Endogenous Retrovirus GAG Protein

6126 Hypoxic Activation of the PERK/eIF2α Arm of the Unfolded Protein Response Promotes Metastasis through Induction of LAMP3
Hilda Mujic, Anika Nagelkerke, Kasper M.A. Rouschop, Stephen Chung, Naz Chaudary, Paul N. Span, Blaise Clarke, Michael Mihosevic, Jenna Sykes, Richard P. Hill, Marianne Koritzinsky, and Bradly G. Wouters

CANCER THERAPY: PRECLINICAL

6138 Adrenomedullin Blockade Suppresses Growth of Human Hormone–Independent Prostate Tumor Xenograft in Mice
Combined Immunostimulatory Monoclonal Antibodies Extend Survival in an Aggressive Transgenic Hepatocellular Carcinoma Mouse Model
Aizea Morales-Kastresana, Miguel F. Samnane, Inmaculada Rodriguez, Asis Palazon, Ivan Martinez-Forero, Sara Labiano, Sandra Hervas-Stubbs, Bruno Sangro, Carmen Ochoa, Ana Rouzaut, Arantza Azpiqueta, Elizabet Bolaños, Maria Jure-Kunkel, Ines Güttgemann, and Ignacio Melero

Glucocorticoid Receptor Antagonism as a Novel Therapy for Triple-Negative Breast Cancer
Maxwell N. Skor, Erin L. Wonder, Masha Kocherginsky, Anju Goyal, Ben A. Hall, Yi Cai, and Suzanne D. Conzen

Dual CDK4/CDK6 Inhibition Induces Cell-Cycle Arrest and Senescence in Neuroblastoma

Efficacy of BET Bromodomain Inhibition in Kras-Mutant Non–Small Cell Lung Cancer
Takeshi Shimamura, Zhao Chen, Margaret Souchay, Julian Carretero, Eiki Kikuchi, Jeremy H. Tchaicha, Yi Cai,拷, and the AECC Cancer Research Foundation

Targeted Nanomedicine for Suppression of CD14 and Simultaneous Cell Death Induction in Ovarian Cancer: An Optimal Delivery of siRNA and Anticancer Drug
Vatsal Shah, Oleh Taratula, Olga B. Garbuzenko, and Tamara Minko

Combination Therapy with a Second-Generation Androgen Receptor Antagonist and a Metastasis Vaccine Improves Survival in a Spontaneous Prostate Cancer Model
Andressa Ardiani, Benedetto Farsaci, Conni J. Rogers, Andy Propper, Zhimin Guo, Thomas H. King, David Apelian, and James W. Hodge

Overcoming IGF1R/IR Resistance through Inhibition of MEK Signaling in Colorectal Cancer Models
Sara A. Flanigan, Todd M. Pitts, Timothy P. Newton, Gillian N. Kulikowski, Aik Choon Tan, Martine C. McManus, Anna Sprefico, Maria C. Kaushya, Heather M. Selby, John J. Tentler, S. Gail Eckhardt, and Stephen Leong

JAK1/2 and Pan-Deacetylase Inhibitor Combination Therapy Yields Improved Efficacy in Preclinical Mouse Models of JAK2V617F-Driven Disease
Emeline Evrot, Nicolas Ebel, Vincent Romanet, Claudia Roelli, Rita Andreou, Zhiyan Qian, Arno Dölemeyer, Ernesta Damassa, Dario Sterker, Robert Cozens, Francesco Hofmann, Masato Murakami, Fabienne Buffert, and Thomas Radimerski

Molecular Chaperone gp96 Is a Novel Therapeutic Target of Multiple Myeloma
Yunpeng Hua, Shai White-Gilbertson, Joshua Kellner, Saleh Rachidi, Saad Z. Usmani, Gabriela Chiosis, Ronald DePinho, Zihai Li, and Bei Liu

Associations between Single-Nucleotide Polymorphisms in the PI3K-PTEN-AKT-mTOR Pathway and Increased Risk of Brain Metastasis in Patients with Non–Small Cell Lung Cancer
Qianxia Li, Ju Yang, Qianqian Yu, Huanlei Wu, Bo Liu, Huihua Xiong, Guangyuan Hu, Jing Zhao, Xinglin Yuan, and Zhongxing Liao

Validation of a Proliferation-Based Expression Signature as Prognostic Marker in Early Stage Lung Adenocarcinoma
Ignacio I. Wistuba, Carmen Behrens, Francesca Lombardi, Susanne Wagner, Junya Fujimoto, M. Gabriela Raso, Lorenzo Spaggiari, Domenico Galletta, Rohyn Riley, Elisha Hughes, Julia Reid, Zaina Sangale, Steven G. Swisher, Neda Kalhor, Cesar A. Moran, Alexander Gustin, Jerry S. Lanchbury, Massimo Barberis, and Edward S. Kim
Promoter Hypomethylation of EpCAM-Regulated Bone Morphogenetic Protein Gene Family in Recurrent Endometrial Cancer
Ya-Ting Hsu, Fei Gu, Yi-Wen Huang, Joseph Liu, Jianhua Ruan, Rui-Lan Huang, Chih-Miin Wang, Chun-Liang Chen, Rohit R. Jadhav, Hung-Cheng Lai, David G. Mutch, Paul J. Goodfellow, Ian M. Thompson, Nameer B. Kirma, and Tim Hui-Ming Huang

Bendamustine and Rituximab in Relapsed and Refractory Hairy Cell Leukemia
Mauricio Burotto, Maryalice Stetler-Stevenson, Evgeny Arons, Hong Zhou, Wyndham Wilson, and Robert J. Kreitman

CANCER THERAPY: CLINICAL

A Phase I Study of an Agonist CD40 Monoclonal Antibody (CP-870,893) in Combination with Gemcitabine in Patients with Advanced Pancreatic Ductal Adenocarcinoma
See related article, p. 6061

Phase I Pharmacokinetic and Pharmacodynamic Study of the First-in-Class Spliceosome Inhibitor E7107 in Patients with Advanced Solid Tumors
Ferry A.L.M. Eskens, Francisco J. Ramos, Herman Burger, James P. O'Brien, Adelaidea Piaza, Maja J.A. de Jonge, Yoshiharu Mizui, Erik A.C. Wiemer, Maria Josepa Carreras, José Baselga, and Josep Tabernero
See related article, p. 6064

Phase I Study of Vismodegib in Children with Recurrent or Refractory Medulloblastoma: A Pediatric Brain Tumor Consortium Study

LETTERS TO THE EDITOR

Conjunctival Melanomas Harbor BRAF and NRAS Mutations—Letter

Conjunctival Melanomas Harbor BRAF and NRAS Mutations—Response
Klaus G. Griewank, Henrike Westekemper, Bastian Schilling, Elisabeth Livingstone, Tobias Schimming, Antje Sucker, Uwe Hillen, Klaus-Peter Steufl, Lisa Zimmer, and Dirk Schadendorf

Proteomic Markers of DNA Repair and PI3K Pathway Activation Predict Response to the PARP Inhibitor BMN 673 in Small Cell Lung Cancer
Robert J. Cardnell, Ying Feng, Lixia Diao, You-Hong Fan, Fatemah Masrorpour, Jing Wang, Yuqiao Shen, Gordon B. Mills, John D. Minna, John V. Heymach, and Lauren A. Byers

Proteomic Markers of DNA Repair and PI3K Pathway Activation Predict Response to the PARP Inhibitor BMN 673 in Small Cell Lung Cancer

PREDICTIVE BIOMARKERS AND PERSONALIZED MEDICINE

Proteomic Markers of DNA Repair and PI3K Pathway Activation Predict Response to the PARP Inhibitor BMN 673 in Small Cell Lung Cancer
Robert J. Cardnell, Ying Feng, Lixia Diao, You-Hong Fan, Fatemah Masrorpour, Jing Wang, Yuqiao Shen, Gordon B. Mills, John D. Minna, John V. Heymach, and Lauren A. Byers

LETTERS TO THE EDITOR

Proteomic Markers of DNA Repair and PI3K Pathway Activation Predict Response to the PARP Inhibitor BMN 673 in Small Cell Lung Cancer
Robert J. Cardnell, Ying Feng, Lixia Diao, You-Hong Fan, Fatemah Masrorpour, Jing Wang, Yuqiao Shen, Gordon B. Mills, John D. Minna, John V. Heymach, and Lauren A. Byers

Conjunctival Melanomas Harbor BRAF and NRAS Mutations
Klaus G. Griewank, Henrike Westekemper, Bastian Schilling, Elisabeth Livingstone, Tobias Schimming, Antje Sucker, Uwe Hillen, Klaus-Peter Steufl, Lisa Zimmer, and Dirk Schadendorf

Conjunctival Melanomas Harbor BRAF and NRAS Mutations

LETTERS TO THE EDITOR

Conjunctival Melanomas Harbor BRAF and NRAS Mutations
Klaus G. Griewank, Henrike Westekemper, Bastian Schilling, Elisabeth Livingstone, Tobias Schimming, Antje Sucker, Uwe Hillen, Klaus-Peter Steufl, Lisa Zimmer, and Dirk Schadendorf

AC icon indicates Author Choice
CME icon indicates this article is available for continuing medical education credit at http://cme.aacrjournals.org
For more information please visit www.aacrjournals.org
ABOUT THE COVER

Cellular internalization of siRNA (red fluorescence) delivered by the nanocarrier (green fluorescence) specifically targeted to cancer cells. Superimposition of red (siRNA) and green (nanocarrier) fluorescence images gives yellow color. For details, see the article by Shah and colleagues on page 6193 of this issue.
Clinical Cancer Research

19 (22)


Updated version
Access the most recent version of this article at:
http://clincancerres.aacrjournals.org/content/19/22

E-mail alerts
Sign up to receive free email-alerts related to this article or journal.

Reprints and Subscriptions
To order reprints of this article or to subscribe to the journal, contact the AACR Publications Department at pubs@aacr.org.

Permissions
To request permission to re-use all or part of this article, contact the AACR Publications Department at permissions@aacr.org.